1. From: Cysteine-rich 61, a Member of the CCN Family, as a Factor Involved in the Pathogenesis of Proliferative Diabetic Retinopathy
Invest. Ophthalmol. Vis. Sci ;50(7): doi: /iovs
Figure Legend:
Vitreous levels of Cyr61 and VEGF and effects of immunodepletion of Cyr61 on chemotactic activity in RF/6A cells in vitreous samples from patients with PDR. (A, B) Vitreous levels of Cyr61 and VEGF were determined by ELISA. Vertical-point figures show levels of Cyr61 (A) and VEGF (B) for the patients with active PDR (n = 56), quiescent PDR (n = 19), or nondiabetic ocular diseases (n = 25). Units for vitreous Cyr61 and VEGF levels are nanograms per milliliter and picograms per milliliter, respectively. *P < 0.01, significantly different when compared with control group. Each assay was in triplicate. † P < 0.01; significantly different between active and quiescent PDR groups. (C) Chemotactic assay showed anti-Cyr61 antibody inhibited PDR vitreous-induced endothelial cell migration. Results of a chemotactic assay represented as the mean number of cells per well ± SD of one of three independent experiments performed in quadruplicate, measured in three high-power fields. Each sample was tested in four wells. Anti-Cyr61 antibody (25 μg/mL) for neutralization of PDR migratory properties was determined as the percent suppression of migration compared with isotype control antibody. † P < 0.05, significantly different from rabbit IgG control. Magnification: ×400. (Note: average Cyr61 levels in the vitreous samples used in chemotaxis assay were 54.0 ± 17.5 ng/mL in the control group, ± 74.4 ng/mL in the active PDR group, and ± 93.2 ng/mL in the active PDR group vitreous pretreated with either rabbit IgG group or anti-Cyr61 antibody. VEGF levels were ± pg/mL in the control group, ± pg/mL in the active PDR group, and ± pg/mL in the active PDR group vitreous pretreated with either rabbit IgG or anti-Cyr61 antibody. Vitreous samples of patients with active PDR were used as the positive control, and those of nondiabetic control patients were used as the negative control. *P < 0.05, significantly different from control patients).
Date of download: 10/27/2017
The Association for Research in Vision and Ophthalmology Copyright © All rights reserved.